VBI-2902

VBI Vaccines Announces Results of Annual General Meeting

Retrieved on: 
Wednesday, June 22, 2022
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Proxy statement, Proxy, SEDAR, Company, Cytomegalovirus, Glioblastoma, Virus, Research, Shareholder, Infection, Hepatitis B, Disease, VBI, Immune system, SEC, VLP, GBM, CMV, VBI-2902, Meeting, Security (finance), Vaccine

Additional information regarding the results of all matters voted upon at the Meeting may be found in the Company's SEC and SEDAR filings.

Key Points: 
  • Additional information regarding the results of all matters voted upon at the Meeting may be found in the Company's SEC and SEDAR filings.
  • VBI Vaccines Inc. (VBI) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease.
  • VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM).
  • VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.

VBI Vaccines Announces Initial Positive Phase 1 Data for Its eVLP Vaccine Candidate Against COVID-19

Retrieved on: 
Tuesday, June 29, 2021
Research, Infectious diseases, FDA, Clinical trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Clinical trials, COVID-19 vaccines, Medicine, Health sciences, Health, VBI-2902, Variation Biotechnologies, COVID-19 vaccine, Vaccine, VBI’s Coronavirus Vaccine Program: VBI-2900, Coronaviruses, VBI Vaccines Inc., VBI’S CORONAVIRUS VACCINE PROGRAM: VBI-2900, CORONAVIRUSES, VBI VACCINES INC.

VBI Vaccines Inc. ( Nasdaq:VBIV ) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced positive Phase 1 data from its Phase 1/2 trial of the first of its enveloped virus-like particle (eVLP) COVID-19 vaccine candidates, VBI-2902a, in healthy adults age 18-54 years of age.

Key Points: 
  • VBI Vaccines Inc. ( Nasdaq:VBIV ) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced positive Phase 1 data from its Phase 1/2 trial of the first of its enveloped virus-like particle (eVLP) COVID-19 vaccine candidates, VBI-2902a, in healthy adults age 18-54 years of age.
  • The data establish a robust human proof-of-concept, at a low dose without the use of a next-generation adjuvant, demonstrating the potency of the eVLP particulate delivery platform against COVID-19.
  • We look forward to sharing further data as we continue to focus on the development of long-term, effective solutions against COVID-19 and other coronaviruses.
  • VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.

VBI Vaccines Announces Publication of Preclinical and Challenge Study Data of its eVLP Vaccine Candidate Against COVID-19 (VBI-2902)

Retrieved on: 
Wednesday, April 28, 2021
Research, Infectious diseases, FDA, Clinical trials, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Health, Medical specialties, Medicine, COVID-19 vaccines, Clinical trials, Infectious diseases, Animal virology, Coronavirus, Glioblastoma, VBI-2902, Hepatitis, Immunogenicity, Coronaviruses, VBI Vaccines Inc., CORONAVIRUSES, VBI VACCINES INC.

\xe2\x80\x9cVBI-2902 has the potential to offer substantial benefit in the prevention of COVID-19, including robust immunogenicity at fewer doses without the need for transportation in ultra-cold chains.

Key Points: 
  • \xe2\x80\x9cVBI-2902 has the potential to offer substantial benefit in the prevention of COVID-19, including robust immunogenicity at fewer doses without the need for transportation in ultra-cold chains.
  • Only seven coronaviruses are known to cause disease in humans, four of which most frequently cause symptoms of the common cold.
  • VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM).
  • VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.\n'